Abstract
502U83, a novel arylmethylaminopropanediol, has proven active in vivo against a panel of murine leukemia and solid tumors as well as in a tumor clonogenic assay against a variety of fresh human cancers. A total of 35 previously treated cancer patients were enrolled in a phase I study of this compound. The maximally tolerated dose (MTD) appears to be 12800 mg/m2/72 h by continuous intravenous infusion with severe granulocytopenia occurring in three of five patients. There were no objective clinical responses. Serum pharmacokinetic parameters were as follows: plasma terminal phase half-life (t( 1/2 )β) = 3.84 h; total body clearance (CL(B)) = 53.1 l/h/m2; volume of distribution at steady state (V(dss)) = 127.9 l/m2; maximum plasma concentration (C(max)) = 3.7 μg/ml (at 12800 mg/m2/72 h dose).
| Original language | English (US) |
|---|---|
| Pages (from-to) | 219-224 |
| Number of pages | 6 |
| Journal | Anti-Cancer Drugs |
| Volume | 3 |
| Issue number | 3 |
| State | Published - 1992 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
- Pharmacology
Cite this
Phase I and pharmacokinetic study of 502U83 (an arylmethylaminopropanediol) in cancer patients. / Lam, Kit; Alberts, D. S.; Peng, Y. M.; Brodar, F.; Matias, B.; Modiano, M.; Tuttle, R.; Sol Lucas, V.; Wargin, W.
In: Anti-Cancer Drugs, Vol. 3, No. 3, 1992, p. 219-224.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Phase I and pharmacokinetic study of 502U83 (an arylmethylaminopropanediol) in cancer patients
AU - Lam, Kit
AU - Alberts, D. S.
AU - Peng, Y. M.
AU - Brodar, F.
AU - Matias, B.
AU - Modiano, M.
AU - Tuttle, R.
AU - Sol Lucas, V.
AU - Wargin, W.
PY - 1992
Y1 - 1992
N2 - 502U83, a novel arylmethylaminopropanediol, has proven active in vivo against a panel of murine leukemia and solid tumors as well as in a tumor clonogenic assay against a variety of fresh human cancers. A total of 35 previously treated cancer patients were enrolled in a phase I study of this compound. The maximally tolerated dose (MTD) appears to be 12800 mg/m2/72 h by continuous intravenous infusion with severe granulocytopenia occurring in three of five patients. There were no objective clinical responses. Serum pharmacokinetic parameters were as follows: plasma terminal phase half-life (t( 1/2 )β) = 3.84 h; total body clearance (CL(B)) = 53.1 l/h/m2; volume of distribution at steady state (V(dss)) = 127.9 l/m2; maximum plasma concentration (C(max)) = 3.7 μg/ml (at 12800 mg/m2/72 h dose).
AB - 502U83, a novel arylmethylaminopropanediol, has proven active in vivo against a panel of murine leukemia and solid tumors as well as in a tumor clonogenic assay against a variety of fresh human cancers. A total of 35 previously treated cancer patients were enrolled in a phase I study of this compound. The maximally tolerated dose (MTD) appears to be 12800 mg/m2/72 h by continuous intravenous infusion with severe granulocytopenia occurring in three of five patients. There were no objective clinical responses. Serum pharmacokinetic parameters were as follows: plasma terminal phase half-life (t( 1/2 )β) = 3.84 h; total body clearance (CL(B)) = 53.1 l/h/m2; volume of distribution at steady state (V(dss)) = 127.9 l/m2; maximum plasma concentration (C(max)) = 3.7 μg/ml (at 12800 mg/m2/72 h dose).
UR - http://www.scopus.com/inward/record.url?scp=0026744623&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026744623&partnerID=8YFLogxK
M3 - Article
C2 - 1525401
AN - SCOPUS:0026744623
VL - 3
SP - 219
EP - 224
JO - Anti-Cancer Drugs
JF - Anti-Cancer Drugs
SN - 0959-4973
IS - 3
ER -